Get our latest issue now

available for iOS, Android & web

latest issue

Latest issue

May features

Country Focus / Germany
Cover story: AMNOG Revisited

How has German health reform impacted pharma pricing and market access and what can the industry learn from the experience?

Customer experience
An experience to remember

Customer experience could be a differentiator for pharma companies. We talk to the former head of customer experience at John Lewis

PharmaTimes Sales Awards
How do you know if you have the best sales people?

Five members from the PharmaTimes Sales Awards steering committee tell us why they support this customer-driven professional development programme

It’s the patient, stupid

Pharma’s business mood seems to be changing. Patient centricity is where it’s at

Benedikte Larsen heads up digital communications at Novo Nordisk

Melissa Lee Interim executive director of the Diabetes Hands Foundation, has lived with type 1 diabetes for more than 20 years. She calls it a beast of an illness 

Click here to see the latest PharmaTimes Magazine

To subscribe go to; digital available from:

download on the app store get it on google play

Outcomes: a gamechanger for pharma

Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?

Healthcare Writer Lynne Taylor

The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.

Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.

Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.

So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here

See what's coming up in the March issue [PDF]

Visions 2014 supplement


Creating a balance between
 reimbursement and innovation

Real-world data
How to plan early

NHS reform
What more does pharma need to do?

We asked you what the big developments in 2014 will be?

Change is key to opportunity
What to adapt for

Salesforce effectiveness
Future-proofing the sales team

Myeloma research
An example of a new R&D model

Visions in a nutshell

The complete Visions 2014 supplement PDF is available to download


Subscription is free to qualifying UK subscribers

To read articles in full and features in the magazine, why not subscribe

Reprints available.

PharmaTimes Magazine print and digital versions have a total circulation of 23,184, including 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.

Follow us: @PharmaTimes on Twitter

Find a job

Website Search

Search News Search Magazine

Business Insight

Elert Signup!